The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
RAF-inhibitor rechallenge therapy in BRAF aberrated pan-cancers: RE-RAFFLE study.
 
Blessie Elizabeth Nelson
No Relationships to Disclose
 
Jason Roszik
No Relationships to Disclose
 
CARMELIA MARIA NOIA BARRETO
No Relationships to Disclose
 
Mirella Nardo
No Relationships to Disclose
 
Jibran Ahmed
No Relationships to Disclose
 
Erick Campbell
No Relationships to Disclose
 
Amber Johnson
No Relationships to Disclose
 
Sarina A. Piha-Paul
Consulting or Advisory Role - CRC Oncology
Research Funding - Abbvie (Inst); ABM (Inst); Acepodia (Inst); Alkermes (Inst); Aminex (Inst); Amphivena Therapetics, Inc. (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squib (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Curis (Inst); Cyclacel (Inst); Daichi Sanko (Inst); ENB Therapeutics (Inst); Epigenetix (Inst); F-Star Beta Limited (Inst); F-Star Therapeutics, Ltd. (Inst); Five Prime Therapeutics (Inst); Gene Quantum (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); Hengrui Pharmaceutical (Inst); HiberCell (Inst); Immorna (Inst); Immunomedics (Inst); Incyte (Inst); Jacobio (Inst); Jiangsu Simcere Pharmaceutical Co. Ltd. (Inst); Lilly (Inst); Lytix Biopharma (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp and Dohme Corp. (Inst); Nectin Therapeutics (Inst); NIH/NCI (Inst); Novartis (Inst); Pfizer (Inst); Phanes Therapeutics (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); Purinomia (Inst); RAPT Therapeutics (Inst); Replimune (Inst); Seagen (Inst); Silverback Therapeutics (Inst); Synlogic (Inst); Taiho Oncology (Inst); Tesaro (Inst); TransThera Biosciences (Inst); ZielBio (Inst)
 
Isabella Claudia Glitza
Honoraria - Amgen
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Leal Therapeutics; Midatech Pharma; Novartis; Sintetica
Speakers' Bureau - Array BioPharma
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Pfizer (Inst)
 
Shiao-Pei S. Weathers
Research Funding - Exelixis; Genentech/Roche (Inst); Mundipharma (Inst)
 
Maria E. Cabanillas
Honoraria - Loxo/Lilly
Consulting or Advisory Role - Bayer; Exelixis; Ignyta; Lilly; Loxo
Research Funding - Eisai; Exelixis; Kura Oncology; Merck; Roche/Genentech
 
Milind M. Javle
Honoraria - AstraZeneca/MedImmune; EMD Serono/Merck; Incyte; Merck; QED Therapeutics; TransThera Biosciences
Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; EMD Serono; incyte; Merck; Mundipharma; oncosil; QED Therapeutics
Other Relationship - Bayer; BeiGene; Incyte; Merck; Merck Serono; Novartis; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - Abbvie; Apeiron Biologics; AstraZeneca; Biovica; Black Diamond Therapeutics; Debiopharm Group; EcoR1 Capital; eFFECTOR Therapeutics; Eisai; Infinity Pharmaceuticals; Karyopharm Therapeutics; Lengo Therapeutics; Loxo; Menarini Group; OnCusp Therapeutics; PACT Pharmaceuticals; Roche; Seagen; Silverback Therapeutics; Tallac Therapeutics; Theratechnologies; Tyra Biosciences; Xencor; Zentalis; Zymeworks
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jounce Therapeutics (Inst); Klus Pharma (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - ESMO; European Organisation for Research and Treatment of Cancer (EORTC)
 
Vivek Subbiah
Consulting or Advisory Role - Helsinn Therapeutics; Loxo/Lilly; MedImmune; Pfizer; Relay Therapeutics
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Relay Therapeutics (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; Foundation Medicine; Helsinn Therapeutics; Novartis; PharmaMar
Other Relationship - Medscape